Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

4.81
-0.1800-3.61%
Post-market: 4.810.00000.00%19:34 EDT
Volume:965.43K
Turnover:4.66M
Market Cap:352.31M
PE:-6.67
High:4.95
Open:4.91
Low:4.79
Close:4.99
52wk High:8.61
52wk Low:4.25
Shares:73.24M
Float Shares:45.48M
Volume Ratio:0.73
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7210
EPS(LYR):-0.7210
ROE:-64.58%
ROA:-25.95%
PB:6.79
PE(LYR):-6.67

Loading ...

Candel Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 18

Candel Therapeutics Inc : Citigroup Raises Target Price to $26 From $22

THOMSON REUTERS
·
Mar 18

U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks

Reuters
·
Mar 18

CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target

TIPRANKS
·
Mar 17

Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline

Reuters
·
Mar 17

BRIEF-Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec

Reuters
·
Mar 17

Candel Therapeutics Inc: Phase 3 Pivotal Study Planned for Initiation in Q2 2026

THOMSON REUTERS
·
Mar 17

Candel Therapeutics Inc: Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec

THOMSON REUTERS
·
Mar 17

Candel Therapeutics reports 25.4-month median overall survival and 50% 24-month survival in CAN-2409 phase 2a NSCLC trial

Reuters
·
Mar 17

Candel Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 14

Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk

TIPRANKS
·
Mar 13

Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate

Benzinga
·
Mar 12

Candel Therapeutics Q4 operating loss misses analyst expectations

Reuters
·
Mar 12

BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million

Reuters
·
Mar 12

Candel Therapeutics Q4 Income From Operations USD -15.752 Million VS. Ibes Estimate USD -13.9 Million

THOMSON REUTERS
·
Mar 12

Candel Therapeutics Q4 Basic EPS USD -0.54

THOMSON REUTERS
·
Mar 12

Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Dow Jones
·
Mar 12

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

GlobeNewswire
·
Mar 09

Candel Therapeutics Grants New Hire Options for 20,000 Shares Under 2025 Inducement Plan

Reuters
·
Mar 03

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 03